Multiple sessions of Ketamine Infusion Therapy offer enhanced and sustained benefits across a range of conditions. For individuals struggling with treatment-resistant depression, anxiety, and PTSD, a series of infusions helps rewire neural pathways, leading to more durable symptom relief and emotional stability. Patients with chronic pain conditions such as fibromyalgia or CRPS often require multiple sessions to effectively reduce pain intensity and improve mobility. Regular treatments support neuroplasticity, reduce relapse rates, and improve overall quality of life, making multi-session protocols an essential part of achieving long-term therapeutic outcomes.
Why Multiple Sessions Are Recommended
1. Cumulative Neurological Impact
3. Condition-Specific Protocols
Recommended Maintenance Schedule
At Sage, we advocate for a structured approach to Ketamine Infusion Therapy. Clinical research and patient outcomes consistently show that a series of infusions provides significantly better, longer-lasting results than a single treatment. Here’s why:
Ketamine works by promoting neuroplasticity—helping the brain form new, healthier neural connections. This process is reinforced with each session, leading to a more substantial and sustained improvement in mood and function.
While some patients may feel initial relief after the first infusion, long-term improvements typically emerge after a course of 6 infusions over 2 to 3 weeks. This schedule allows for stabilization of symptoms and prevents regression.
After your initial 6-session series, our team will work with you to determine the best maintenance plan, which may include:
Aan Het Rot, M., Zarate, C. A., Charney, D. S., & Mathew, S. J. (2012). Biological Psychiatry, 72(7), 537–547. https://doi.org/10.1016/j.biopsych.2012.05.003
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., Aan Het Rot, M., ... & Iosifescu, D. V. (2013). Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biological Psychiatry, 74(4), 250–256. https://doi.org/10.1016/j.biopsych.2012.06.022
Shiroma, P. R., Thuras, P., Johns, B., Luckenbaugh, D., & Wels, J. (2014). Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment-resistant depression. Journal of Affective Disorders, 155, 123–129. https://doi.org/10.1016/j.jad.2013.10.036